Tango Therapeutics
Investors
Join Us
Contact
Science
Approach
Platform
Publications + Posters
Pipeline
Programs
PRMT5
Clinical Trials
Leadership
Home
Science
▼
Approach
Platform
Publications + Posters
Pipeline
Programs
▼
PRMT5
Clinical Trials
Leadership
Join Us
Investors
▼
Overview
News & Events
▼
News Releases
Events & Presentations
Governance
▼
Overview
Executive Leadership
Board of Directors
Committee Composition
Stock Information
▼
Stock Quote & Chart
Financials
▼
SEC Filings
Resources
▼
Investor FAQs
Email Alerts
Contact IR
Contact
Publications + Posters
|
ESMO
October 2026
A Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutant (MTAPdel/RASmut) metastatic PDAC and NSCLC
Alexander Spira, et al.
|
Covalent Drug Discovery & Development Summit
October 2026
Mass Spectrometry-Based Kinetic and Site-Specific Profiling of Covalent Inhibitors Targeting VRK1
Mu-Sen Liu
|
Journal of Biological Chemistry
October 2026
Genetic and biochemical screens identify MGAT1 as a druggable glycosyltransferase target in STK11-mutant lung cancer
Kiera M. Vassallo, et al.
|
Discovery on Target
September 2026
Covalent and Non-Covalent Lead Generation Strategies for VRK1, a Paralog Synthetic Lethal Target in Cancer
Kasia Handing
|
Gordon Research Conference: Enzymes, Coenzymes and Metabolic Pathways
July 2026
Mass Spectrometry-Based Kinetic and Site-Specific Profiling of Covalent Inhibitors Targeting VRK1
Mu-Sen Liu
Learn more about our drug discovery programs and explore our pipeline.